It might be prudent to make a point of collecting a little more cash in the near future, and worry a little less about growth ...

While Pfizer's dividend yield is clearly much higher than Merck's, both have relatively attractive yields today. And you ...

Pfizer Inc. (NYSE:PFE) hasn’t performed well in recent years, with its stock declining more than 26% over the past decade.

Pfizer Inc. (NYSE:PFE) is one of the best cheap stocks under $50 to buy now. On July 10, Morgan Stanley analyst Terrence ...

Pfizer, in partnership with Bristol Myers Squibb, has launched a direct-to-patient sales strategy for Eliquis®, aiming to ...

The completion of this study may positively influence Pfizer’s stock performance by demonstrating the effectiveness and safety of INLYTA® in real-world settings, potentially boosting investor ...

The purpose of investing in stocks is to make money, not lose it. So selling shares at a loss can be very upsetting. In this ...

U.S. Bancorp notched a rise in earnings for the latest quarter as it benefited from a lower loan-loss provision and growth in fee income. The healthcare-products maker trimmed and narrowed its ...

Merck & Co., Inc. outshines Gilead Sciences, Inc. with stronger dividend growth, valuation metrics & PEGY ratio. Click for ...

Shares of Johnson & Johnson climbed 6.8% in morning trading, enough to pace the S&P 500 index's SPX gainers. They were also headed for their biggest one-day gain and best postearnings reaction since ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $133.42, a high estimate of $155.00, and a low estimate of $110.00. A negative shift in sentiment is evident ...

Shares are down in the year to date and 20% off their 52-week high, but analysts see 30% upside ahead for Pfizer.